0242 GMT December 11, 2017
Niemann-Pick disease type C1 is a rare, fatal genetic disorder that affects children and adolescents causing progressive decline in neurological and cognitive function, UPI reported.
The study, by the National Institutes of Health, was published in The Lancet, and show the drug 2-hydroxypropyl-cyclodextrin, or VTS-270, was effective at slowing the progression of Niemann-Pick disease type C1 in a clinical trial.
Dr. Forbes Porter, clinical director at the National Institutes of Health (NIH)'s Eunice Kennedy Shriver National Institute of Child Health and Human Development, said, "The results are very encouraging and support continued development of VTS-270 for treating NPC1.
"Compared to untreated patients we followed in an earlier study, participants who received VTS-270 scored better on a scale used to evaluate disease severity and progression, including elements such as speech, cognition and mobility."
VTS-270 was tested on 14 participants aged between four and 23 who received the drug once a month for 12 to 18 months and another group of three participants who received the drug every two weeks for 18 months.
Participants were initially divided into two groups but when it appeared the drug was well tolerated, researchers increased the dose for all participants.
Researchers measured cholesterol levels because NPC1 symptoms come from cholesterol buildup in brain cells and found that after treatment with VTS-270 — a molecule derived from cholesterol metabolism in neurons had increased.
Participants also had lower levels of two proteins indicated in brain injury suggesting that there was less damage to the brain.
Participants who received VTS-270 had lower scores, indicative of less severe disease, in cognition and speech tests.
VTS-270 also did not show adverse side effects and showed it could improve cholesterol metabolism in neurons targeting the causes of symptoms of the disease.